Chemistry42

?? Silicon Valley, see you next week! ?? Excited to share that Petrina Kamya, Ph.D., our Global Head of AI Platforms & VP, President of Insilico Medicine Canada, will be speaking at VLAB's Future of Drug Discovery event next week! She’ll be diving into one of the hottest topics in biotech: ?? Is Generative AI the Breakthrough in Drug Development? ?? Thursday, March 20, 2025 ?? Silicon Valley Bank Experience Center ? 6 - 8 PM PST Generative AI is transforming the way we discover and develop new drugs, and Petrina will be sharing insights on how AI-driven platforms are accelerating innovation. If you’re in Silicon Valley, don’t miss this opportunity to explore the future of AI in life sciences! ?? Join the conversation & connect with us there! Email [email protected] and head to the VLAB website here: https://lnkd.in/e8mBmbak #InsilicoMedicine #AIinDrugDiscovery #GenerativeAI #BiotechInnovation #VLAB #AIPlatforms

Incredible job, Jue Wang ??

?? Attention Startups and Academia! Have you browsed the Pay-As-You-Go options with Chemistry42??? Academia and startups can directly purchase tokens on the Chemistry42 website. ?? AI-powered molecular generation – now flexible & affordable. ?? No contracts. No commitments. Just results. ?? Start using Chemistry42 today: https://lnkd.in/e_TcjxvK #AI #DrugDiscovery #Biotech #MachineLearning

Great news, my friends - we got $110 million in series E funding led by one of the largest publicly-traded asset management firms in Asia, Value Partners Group . This round follows our announcement of the top line results from our Phase IIa clinical results for Rentosertib (ISM018-055) in IPF and multiple other milestones on the clinical side (TEAD and MAT2A inhibitors are also now in Phase I and PHD1/2 inhibitor for IBD completed two Phase Is). However, the Phase 2a readout is not the only reason for this round. The healthcare partner at Value Partners, Dr Chuen Yan Leung who has a PhD from the University of Cambridge, followed the company since his time in academia and did a lab seminar on experimental validation of our Generative Tensorial Reinforcement Learning (GENTRL) paper in 2019 in Nature Biotechnology. Since then, we have taken both the generative platforms and the reinforcement learning pipeline to a completely new level with over 700 different models. The funding will be used to progress the therapeutic pipeline and to advance and expand our end-to-end generative AI platform. In the comments are links to pieces by the wonderful Saritha Rai of Bloomberg (Exclusive), Conor Hale of Fierce, who knows our company better than anyone for many years, and Kyle LaHucik of Endpoints. Congratulations to the team, to all of the investors and partners who supported us, and to patients who now have the higher chance of seeing the drugs reach the clinic. We are here for the patients and when it comes to Aging, all of us are patients so check out our papers on TNIK and dual purpose aging- and disease-targeting therapeutics.

In the #ClosingKeynote talk of the #AIinDrugDiscovery Conference, Darren Green, Director of?ChemPlus Cheminformatics Consultants led a panel of experts who discussed if AI will live up to its current hype? Key takeaways? AI agents are still limited in use, but will be a key part of everyday working in years to come, as these agents improve. The panellists discussed what excites them most in the AI in Drug Discovery space, where AI is generating most value, and what is currently in the ‘hype’ phase. One big question coming out of the discussion, where would you invest: model development or data generation? Let us know your thoughts in the comments below ?? Thank you to our expert speakers: ?? Peter Clark, PhD ,?VP of Computational Drug Design, Novo Nordisk ?? Petrina Kamya, Ph.D.,?President, Insilico Medicine Canada Inc., and Global Head of AI Platforms, VP, Insilico Medicine ?? Fred Manby,?Co-Founder and CTO, Iambic Therapeutics ...And our conference chair for the day: ?? Maureen Makes,?VP of Engineering at Recursion #AIDrugDis #AIDrugDis25

?? Day 2 begins at the SAE Media Group 's AI in Drug Discovery Conference in London. The Pharma.AI Team is here to connect with industry leaders, and lead a very important session today: An end-to-end AI platform for novel drug discovery. ?? Petrina Kamya, Ph.D., Global Head of AI Platforms, is taking the stage today to share insights on how AI is transforming drug discovery, accelerating timelines, and unlocking novel therapeutics. Don’t miss this session at 4pm, at the Hilton London Kensington. ?? Jan Szollos, MBA, Director of BD, is actively engaging with industry leaders, exploring exciting opportunities to advance AI-driven drug development. If you're attending, let’s connect and discuss how AI is shaping the future of pharma! Interested in reaching out after the event? Email us: [email protected] #AIDrugDiscovery #AIinPharma #InsilicoMedicine #SAEConference #AIDD2025

?? Coming Soon: Nach01 – The Next AI Breakthrough in Drug Discovery! ?? ?? What is Nach01? Nach01 represents the next evolution of AI-driven target discovery and drug design, leveraging cutting-edge machine learning to accelerate breakthrough therapies. You can seamlessly integrate and enhance your pipeline by fine-tuning our foundation model using your data. ?? Why it matters? Traditional drug discovery is slow, costly, and complex. Nach01 is designed to optimize and streamline this process, bringing novel therapeutics to patients faster. ?? Stay tuned – big things are coming! Watch the teaser video and be part of the next wave of innovation in biotech. Visit https://lnkd.in/eWDfZDMd to learn more!

??First end-to-end generative AI-assisted drug ISM001-055 receives official generic name #Rentosertib from USAN Insilico recently announced that its breakthrough drug candidate for idiopathic pulmonary fibrosis (#IPF) – Rentosertib (formerly known as ISM001-055) – has been granted an official generic name by the United States Adopted Names (USAN) Council. Rentosertib stands as the first investigational drug in which both the biological target and the therapeutic compound were discovered using generative AI. Idiopathic Pulmonary Fibrosis (IPF) is a chronic, scary lung disease characterized by a progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries poor prognosis, with a median survival of 3 to 4 years. Current treatments, including antifibrotic drugs, can slow disease progression but do not stop or reverse it, leaving a significant unmet need for more effective, disease-modifying therapies. Insilico adopted a pioneering approach to anti-IPF research by leveraging its proprietary Pharma.AI platform to discover innovative therapeutics with the potential to halt or even reverse disease progression. The process began with PandaOmics, the platform’s biology engine, which analyzed vast omics and clinical datasets to identify #TNIK (TRAF2 and NCK-interacting kinase) as a promising novel target for IPF. Building on this discovery, researchers used Chemistry42, the platform’s generative chemistry engine, to swiftly design and optimize new small-molecule compounds targeting TNIK, leading to the nomination of Rentosertib as the preclinical candidate. Full release can be found in the comments below ??

Insilico Medicine announces the deployment of the first bipedal humanoid in its AI-powered, fully robotic drug discovery laboratory. Learn more: https://lnkd.in/ebUW-j6C #humanoid #humanoids #humanoidrobot #humanoidrobots

?? ????-?????????????? ???????? ?????????????????? ???? ????????????! At #DDIP2025, Petrina Kamya, from Insilico Medicine delivered an insightful presentation on "????????-?????????? ?????????????? ???? ????-???????????? ???????? ?????????????????? ?????? ??????????????????????." ?? She highlighted how AI is accelerating drug discovery by optimizing target identification, reducing development timelines, and enhancing real-world applications in precision medicine. Stay tuned for more updates. #AIinPharma #DrugDiscovery #DDIP2025 #HealthcareInnovation #InsilicoMedicine #Highlights